Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1/2 4Phase 3 3Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 18Recruiting 10Active not recruiting 10Terminated 5Unknown 4Withdrawn 2Not yet recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Meningeal Carcinomatosis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 21fludarabine 17Specimen Handling 13Magnetic Resonance Spectroscopy 10pembrolizumab 9Nivolumab 9Radiotherapy 7Cisplatin 7fludarabine phosphate 5Injections 5tislelizumab 4daratumumab 4Rituximab 4Paclitaxel 4Ipilimumab 4Interleukin-2 4Immune Checkpoint Inhibitors 4Gemcitabine 4Fluorouracil 4Drug Therapy 4Doxorubicin 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3toripalimab 3X-Rays 3Radiosurgery 3Platinum 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × osimertinib × Clear all
NCT07361705 2026-01-23

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 1 Not yet recruiting
42 enrolled
CNS

Meningeal Carcinomatosis

NCT06067776 2023-10-05

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

University of California, Davis

Phase 1 Not yet recruiting
36 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡